Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -136.36% is in line with its 4-year average of -139.60%, around the middle of its 4-year range (-328.33%–-40.65%).
As of the fiscal period ended Tuesday, June 30, 2026. 41.31% above its 12-month average of -232.34%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -136.36%.
RETURN ON EQUITY (ROE)
-136.36%
RETURN ON EQUITY (ROE) AVG TTM
-232.34%
RETURN ON EQUITY (ROE) AVG 3Y
-126.87%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+41.31%
CURRENT VS 3Y AVG
-7.48%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-224.59%
vs the sector median at left
P3 Health Partners Inc.
Market Cap
$18.80M
Return on Equity (ROE)
-136.36%
TTM Avg
-232.34%
3Y Avg
-126.87%
5Y Avg
N/A
Market Cap
$19.14M
Return on Equity (ROE)
-2067.81%
TTM Avg
-13234.78%
3Y Avg
-6645.16%
5Y Avg
-6645.16%
Market Cap
$18.67M
Return on Equity (ROE)
-75.34%
TTM Avg
-0.67%
3Y Avg
-77.39%
5Y Avg
-61.36%
Market Cap
$17.99M
Return on Equity (ROE)
N/A
TTM Avg
-3014.83%
3Y Avg
-1589.49%
5Y Avg
-1032.64%
Market Cap
$17.74M
Return on Equity (ROE)
-34.50%
TTM Avg
-796.82%
3Y Avg
-138.82%
5Y Avg
-407.45%
Market Cap
$17.57M
Return on Equity (ROE)
-117.98%
TTM Avg
-84.94%
3Y Avg
-64.05%
5Y Avg
-76.29%
Market Cap
$20.16M
Return on Equity (ROE)
-351.86%
TTM Avg
-122.41%
3Y Avg
-86.06%
5Y Avg
-64.41%
Market Cap
$17.11M
Return on Equity (ROE)
-54.45%
TTM Avg
-33.23%
3Y Avg
-44.23%
5Y Avg
-52.50%
Market Cap
$16.76M
Return on Equity (ROE)
-71.57%
TTM Avg
-65.12%
3Y Avg
-85.39%
5Y Avg
-90.29%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| P3 Health Partners Inc. (PIII) | $18.80M | -136.36% | -232.34% | -126.87% | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $19.14M | -2067.81% | -13234.78% | -6645.16% | -6645.16% |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.67M | -75.34% | -0.67% | -77.39% | -61.36% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $17.99M | N/A | -3014.83% | -1589.49% | -1032.64% |
| PAVmed Inc. (PAVM)vs › | $17.74M | -34.50% | -796.82% | -138.82% | -407.45% |
| Cosmos Health Inc. (COSM)vs › | $17.57M | -117.98% | -84.94% | -64.05% | -76.29% |
| NextCure, Inc. (NXTC)vs › | $20.16M | -351.86% | -122.41% | -86.06% | -64.41% |
| Lipocine Inc. (LPCN)vs › | $17.11M | -54.45% | -33.23% | -44.23% | -52.50% |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.76M | -71.57% | -65.12% | -85.39% | -90.29% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.70M | -101.76% | -188.04% | -167.76% | -134.95% |
ROE
-136.4%
ROA
-15.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -136.36% |
| 2025-06-30 | -328.33% |
| 2025-03-31 | -217.60% |
| 2024-12-31 | -178.90% |
| 2024-09-30 | -85.21% |
| 2024-06-30 | -41.64% |
| 2024-03-31 | -45.89% |
| 2023-12-31 | -40.65% |
| 2023-09-30 | -67.22% |
| 2022-09-30 | -315.60% |
| 2022-06-30 | -246.07% |
| 2022-03-31 | -54.15% |
| 2021-12-31 | -57.20% |
